Brief: CSPC Pharmaceutical Says SYS6043 Granted Breakthrough Therapy Designation In China For Platinum-Resistant Ovarian Cancer
02/07/2026 16:27
BRIEF-CSPC Pharmaceutical Says SYS6043 Granted Breakthrough Therapy Designation In China For Platinum-Resistant Ovarian Cancer July 2 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK:
SYS6043 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR PLATINUM-RESISTANT OVARIAN CANCER
GRANTED BREAKTHROUGH THERAPY DESIGNATION BY NMPA
Further company coverage: 1093.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines